Efficacy Study of Switching to a Lutenizing Hormone-releasing Hormone (LHRH) Antagonist From a LHRH Agonist to Treat Progressive Castrate Resistant Prostate Cancer (CRPC)
by on Thursday, June 28th, 2012 | No Comments
Condition: Prostate Neoplasm
Intervention: Drug: Degarelix
Sponsors: British Columbia Cancer Agency; British Columbia Cancer Agency; Ferring Pharmaceuticals
Not yet recruiting – verified June 2012